Literature DB >> 9160207

Use of extracorporeal liver assist device and auxiliary liver transplantation in fulminant hepatic failure.

M McCarthy1, A J Ellis, J A Wendon, N Heaton, M Rela, M Buxton-Thomas, R D Hughes, B C Portmann, R Williams.   

Abstract

The case history of a 14-year-old boy with fulminant hepatic failure secondary to non-A, non-B hepatitis who fulfilled selection criteria for orthotopic liver transplantation is described. Two forms of liver support were used (extracorporeal liver assist device and an auxiliary partial orthotopic liver transplantation) to provide additional time to allow spontaneous recovery to occur. During the 66 h of extracorporeal haemoperfusion through the device, haemodynamic stability was maintained along with improvements in serum bilirubin (555 to 381 mumol/l), and international normalized ratio (INR) (3.7 to 2.9). Deterioration in these parameters was observed following cessation of treatment and 10 h later, after a donor liver had become available, an auxiliary transplant was performed. Clinical recovery, though initially slow, was eventually complete, with histopathological and scintigraphic evidence of full liver regeneration at 3 months. Withdrawal of his immunosuppressive drugs began at 6 months and was complete by 14 months after auxiliary transplantation. He has since remained well with normal liver function tests. Temporary liver support may provide additional time for spontaneous recovery of the native liver to occur in selected cases of fulminant hepatic failure, even when criteria are fulfilled for orthotopic liver grafting.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9160207     DOI: 10.1097/00042737-199704000-00017

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  1 in total

1.  Liver transplantation after organ preservation with normothermic extracorporeal perfusion.

Authors:  M R Schön; O Kollmar; S Wolf; H Schrem; M Matthes; N Akkoc; N C Schnoy; P Neuhaus
Journal:  Ann Surg       Date:  2001-01       Impact factor: 12.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.